ArticleAnnals of the rheumatic diseases2022

Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.

Matthew J Koster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.